AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39158832 — intervention group
Group type: EXPERIMENTAL
Intervention: Achalasia
Number of subjects: 118
Study 39158832 — intervention group
Group type: COMPARATOR
Intervention: Functional gastrointestinal disorders (FGIDs)
Number of subjects: 118
Study 39158833 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII) at an initial dose of 200 U/kg, with subsequent doses based on clinical measures; median total dose was 548.4 U/kg (range: 198-1803 U/kg) with a median of 3.0 infusions per patient.
Number of subjects: 5
Study 39158851 — intervention group
Group type: COMPARATOR
Intervention: Group Mindfulness-Based Intervention (MBI) via videoconference
Number of subjects: 811
Study 39158851 — intervention group
Group type: COMPARATOR
Intervention: Self-paced Mindfulness-Based Intervention (MBI)
Number of subjects: 811
Study 39158851 — intervention group
Group type: COMPARATOR
Intervention: Group Mindfulness-Based Intervention (MBI)
Number of subjects: 811
Study 39158893 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized nicardipine release implants (10 implants at 4 mg each) plus standard of care
Number of subjects: 41
Study 39158893 — intervention group
Group type: COMPARATOR
Intervention: Aneurysm repair alone plus standard of care
Number of subjects: 41
Study 39158894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n=619)
Number of subjects: 1384
Study 39158894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=626)
Number of subjects: 1384
Study 39158894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1384
Study 39158894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1384
Study 39158903 — intervention group
Group type: EXPERIMENTAL
Intervention: App platform-facilitated collaborative palliative care intervention
Number of subjects: 0
Study 39158912 — intervention group
Group type: COMPARATOR
Intervention: Message from clinician (group 2)
Number of subjects: 3051
Study 39158912 — intervention group
Group type: EXPERIMENTAL
Intervention: Message from news story and clinician (group 3)
Number of subjects: 3051
Study 39158912 — intervention group
Group type: EXPERIMENTAL
Intervention: Message from family member and clinician (group 4)
Number of subjects: 3051
Study 39158914 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 172
Study 39158914 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 172
Study 39158916 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK16149 40 mg/d
Number of subjects: 725
Study 39158916 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK16149 80 mg/d
Number of subjects: 725
Study 39158916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 39158946 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized serum β2-microglobulin (B2M)
Number of subjects: 97
Study 39158946 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized serum creatinine (Scr)
Number of subjects: 97
Study 39158946 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant B2M levels
Number of subjects: 97
Study 39158987 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 75
Study 39158987 — intervention group
Group type: COMPARATOR
Intervention: non-COVID ICU controls
Number of subjects: 75
Study 39159183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)-based antiretroviral therapy
Number of subjects: 1920
Study 39159190 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Occupational Therapy Intervention program (EOTIPS)
Number of subjects: 60
Study 39159260 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-IVF
Number of subjects: 115
Study 39159260 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 115
Study 39159269 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR Sick Child Job Aid (SCJA) with CRP measurement
Number of subjects: 1280
Study 39159269 — intervention group
Group type: COMPARATOR
Intervention: Integrated Community Care Management (iCCM) SCJA (control)
Number of subjects: 1280
Study 39159398 — intervention group
Group type: EXPERIMENTAL
Intervention: Visitect CD4 test
Number of subjects: 1495
Study 39159403 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 268
Study 39159403 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (30 Gy)
Number of subjects: 268
Study 39159418 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib with fulvestrant
Number of subjects: 708
Study 39159450 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychoeducation about cancer-related sexual morbidity
Number of subjects: 320
Study 39159450 — intervention group
Group type: COMPARATOR
Intervention: Standard psychoeducation about cancer-related sexual morbidity
Number of subjects: 320
Study 39159450 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for discussing concerns with health care providers (received)
Number of subjects: 320
Study 39159450 — intervention group
Group type: COMPARATOR
Intervention: Communication skills training for discussing concerns with health care providers (not received)
Number of subjects: 320
Study 39159450 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for discussing concerns with a partner (received)
Number of subjects: 320
Study 39159450 — intervention group
Group type: COMPARATOR
Intervention: Communication skills training for discussing concerns with a partner (not received)
Number of subjects: 320
Study 39159450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimacy promotion skills training (received)
Number of subjects: 320
Study 39159450 — intervention group
Group type: COMPARATOR
Intervention: Intimacy promotion skills training (not received)
Number of subjects: 320
Study 39159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 0
Study 39159624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39159648 — intervention group
Group type: COMPARATOR
Intervention: Standard nab-paclitaxel-gemcitabine treatment
Number of subjects: 325
Study 39159648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating nab-paclitaxel-gemcitabine and gemcitabine alone
Number of subjects: 325
Study 39159822 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia group (TSK score ≥ 37)
Number of subjects: 140
Study 39159822 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia group
Number of subjects: 140
Study 39159822 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 140
Study 39159822 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 140
Study 39159822 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from injury to surgery
Number of subjects: 140
Study 39159865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild glucose intolerance
Number of subjects: 827
Study 39159997 — intervention group
Group type: EXPERIMENTAL
Intervention: BEL/RTX (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous rituximab 1000 mg at weeks 4 and 6)
Number of subjects: 263
Study 39159997 — intervention group
Group type: COMPARATOR
Intervention: BEL/PBO (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous placebo at weeks 4 and 6)
Number of subjects: 263
Study 39159997 — intervention group
Group type: EXPERIMENTAL
Intervention: BEL/RTX
Number of subjects: 263
Study 39159997 — intervention group
Group type: COMPARATOR
Intervention: BEL/PBO
Number of subjects: 263
Study 39160081 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicolith appendicitis without other complications
Number of subjects: 78
Study 39160081 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicolith appendicitis with complications (appendiceal gangrene, perforation, and/or abscess)
Number of subjects: 78
Study 39160086 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HFpEF
Number of subjects: 40
Study 39160086 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 39160092 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 230
Study 39160092 — intervention group
Group type: COMPARATOR
Intervention: Non-General Anaesthesia (Non-GA)
Number of subjects: 230
Study 39160109 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenyan national diarrheal policy frameworks, plans, strategies, laws, institutional frameworks and operational guidelines
Number of subjects: 0
Study 39160109 — intervention group
Group type: EXPERIMENTAL
Intervention: Policies for advocacy, health communication, social mobilisation, logistics management, and prevention strategies
Number of subjects: 0
Study 39160109 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnosis, vaccine development and deployment, and strong funding commitment
Number of subjects: 0
Study 39160110 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNO)
Number of subjects: 500
Study 39160110 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 500
Study 39160146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal treatment (sound therapy + electrical tongue stimulation)
Number of subjects: 112
Study 39160146 — intervention group
Group type: COMPARATOR
Intervention: Sound-only stimulation
Number of subjects: 112
Study 39160255 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk expression subtype at progression
Number of subjects: 1143
Study 39160255 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy targets
Number of subjects: 1143
Study 39160351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (DBS)
Number of subjects: 4
Study 39160351 — intervention group
Group type: COMPARATOR
Intervention: Continuous deep brain stimulation (DBS)
Number of subjects: 4
Study 39160459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for at least 8 weeks, followed by 5 or 10 mg twice daily at investigator's discretion
Number of subjects: 110
Study 39160459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 110
Study 39160468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (TRF) vitamin E, 50 mg daily for six months
Number of subjects: 29
Study 39160468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 39160528 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 388
Study 39160528 — intervention group
Group type: COMPARATOR
Intervention: Matched comparators without COVID-19
Number of subjects: 388
Study 39160566 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH, a web-based social learning and cognitive behavior therapy (SLCBT) intervention
Number of subjects: 460
Study 39160566 — intervention group
Group type: COMPARATOR
Intervention: Educational web-based safety comparison condition (EC)
Number of subjects: 460
Study 39160612 — intervention group
Group type: EXPERIMENTAL
Intervention: Air purifiers used in homes, reported running virtually 24 hours every day, with approximately 80% on medium setting.
Number of subjects: 150
Study 39160612 — intervention group
Group type: EXPERIMENTAL
Intervention: Air purifiers used in homes, with structured interviews conducted with a subset of 26 participants.
Number of subjects: 150
Study 39160612 — intervention group
Group type: EXPERIMENTAL
Intervention: Air purifiers used in homes, tolerance to noise measured at 30-day and 90-day visits.
Number of subjects: 150
Study 39160612 — intervention group
Group type: EXPERIMENTAL
Intervention: Electricity consumption recorded using HOBO monitors from a subset of 45 participants.
Number of subjects: 150
Study 39160614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudges to patients and/or clinicians
Number of subjects: 0
Study 39160614 — intervention group
Group type: COMPARATOR
Intervention: No nudges (control group)
Number of subjects: 0
Study 39160651 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Number of subjects: 0
Study 39160668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic liner
Number of subjects: 0
Study 39160668 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene liner
Number of subjects: 0
Study 39160756 — intervention group
Group type: EXPERIMENTAL
Intervention: +EAA
Number of subjects: 17
Study 39160756 — intervention group
Group type: COMPARATOR
Intervention: +CHO
Number of subjects: 17
Study 39161224 — intervention group
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 8
Study 39161224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 39161543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 mg with intravenous obinutuzumab 1000 mg
Number of subjects: 66
Study 39161559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified, fully immersive and stroke-specific virtual reality intervention for 10 weeks starting at week 3 poststroke
Number of subjects: 94
Study 39161559 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study 39161801 — intervention group
Group type: EXPERIMENTAL
Intervention: blinded i.v. iron (1000 mg ferric derisomaltose)
Number of subjects: 60
Study 39161801 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 39161865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual counseling training based on the PLISSIT model (3 sessions)
Number of subjects: 74
Study 39161865 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 74
Study 39161865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual counseling training based on the PLISSIT model
Number of subjects: 74
Study 39161870 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict bundled care treatment (BCT) over the first 72 hours during acute hospital care
Number of subjects: 681
Study 39161870 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 681
Study 39161962 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlilumab followed by Atezolizumab with palliative radiation therapy (RT)
Number of subjects: 15
Study 39162035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE) treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily)
Number of subjects: 24
Study 39162035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE) treatment
Number of subjects: 24
Study 39162035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 39162209 — intervention group
Group type: EXPERIMENTAL
Intervention: SPY fluorescence angiography
Number of subjects: 332
Study 39162209 — intervention group
Group type: COMPARATOR
Intervention: Control (historic cohort without SPY)
Number of subjects: 332
Study 39162220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid; specific dosage and duration not mentioned
Number of subjects: 0
Study 39162334 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 206
Study 39162334 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 206
Study 39162385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic compression bandage
Number of subjects: 310
Study 39162385 — intervention group
Group type: COMPARATOR
Intervention: Conventional compression bandage
Number of subjects: 310
Study 39162632 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA plus CT-FFR
Number of subjects: 105
Study 39162632 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA plus CT perfusion
Number of subjects: 105
Study 39162632 — intervention group
Group type: COMPARATOR
Intervention: CCTA alone
Number of subjects: 105
Study 39162632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential CCTA plus CT-FFR and CT perfusion
Number of subjects: 105
Study 39162633 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave dispersion slope (DS)
Number of subjects: 124
Study 39162633 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation coefficient (AC)
Number of subjects: 124
Study 39162633 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave speed (SWS)
Number of subjects: 124
Study 39162633 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric US imaging markers
Number of subjects: 124
Study 39162634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium 177 (specific dosage and duration not mentioned)
Number of subjects: 0
Study 39162825 — intervention group
Group type: EXPERIMENTAL
Intervention: NPi ≤ 2
Number of subjects: 710
Study 39162825 — intervention group
Group type: EXPERIMENTAL
Intervention: qPLR < 4%
Number of subjects: 710
Study 39162825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined qPLR < 4% and NPi ≤ 2 with NSE > 60 μg/L
Number of subjects: 710
Study 39162872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + chemotherapy (SOX or CAPOX)
Number of subjects: 717
Study 39162872 — intervention group
Group type: COMPARATOR
Intervention: Placebo + chemotherapy (SOX or CAPOX)
Number of subjects: 717
Study 39162882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) during venovenous extracorporeal membrane oxygenation (VV-ECMO)
Number of subjects: 165
Study 39162882 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning during venovenous extracorporeal membrane oxygenation (VV-ECMO)
Number of subjects: 165
Study 39162882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) during VV-ECMO
Number of subjects: 165
Study 39162912 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) provided in bilateral frontal montage, F3 anode, F4 cathode, 2 mA, for 30 min, in a 6-week trial, for total 21 sessions
Number of subjects: 44
Study 39163044 — intervention group
Group type: EXPERIMENTAL
Intervention: Maya mobile app-based cognitive behavioral therapy (CBT) intervention for 6 weeks with text message-based incentives (gain-framed, loss-framed, gain-social support)
Number of subjects: 59
Study 39163044 — intervention group
Group type: EXPERIMENTAL
Intervention: Maya mobile app-based cognitive behavioral therapy (CBT) intervention
Number of subjects: 59
Study 39163043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean Cut multimodal surgical quality improvement program
Number of subjects: 9755
Study 39163043 — intervention group
Group type: COMPARATOR
Intervention: Control period (before implementation of the intervention)
Number of subjects: 9755
Study 39163043 — intervention group
Group type: EXPERIMENTAL
Intervention: High compliance with perioperative standards (regardless of trial arm)
Number of subjects: 9755
Study 39163327 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of face-down positioning (FDP)
Number of subjects: 0
Study 39163327 — intervention group
Group type: COMPARATOR
Intervention: 7 days of face-down positioning (FDP)
Number of subjects: 0
Study 39163327 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of FDP
Number of subjects: 0
Study 39163327 — intervention group
Group type: COMPARATOR
Intervention: 7 days of FDP
Number of subjects: 0
Study 39163362 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided treatment
Number of subjects: 468
Study 39163362 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided treatment
Number of subjects: 468
Study 39163362 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 468
Study 39163371 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 levels measured at 48 hours after PCI
Number of subjects: 205
Study 39163371 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 levels measured at 24 hours after PCI
Number of subjects: 205
Study 39163415 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing tools and approaches in palliative oncology care
Number of subjects: 300
Study 39163415 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative phase with semi-structured interviews
Number of subjects: 300
Study 39163415 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative study with self-questionnaires (BMQ and rPATD)
Number of subjects: 300
Study 39163415 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxiliary study assessing health literacy
Number of subjects: 300
Study 39163505 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 2259
Study 39163505 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 2259
Study 39163505 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 2259
Study 39163589 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time Feedback (RTF) supported home exercise
Number of subjects: 70
Study 39163589 — intervention group
Group type: COMPARATOR
Intervention: Paper instructions for exercise guidance
Number of subjects: 70
Study 39163591 — intervention group
Group type: EXPERIMENTAL
Intervention: uTECH+YMHP (SMS text messages informed by ML algorithm + YMHP counseling)
Number of subjects: 330
Study 39163591 — intervention group
Group type: COMPARATOR
Intervention: YMHP (4 motivational interviewing-based counseling sessions)
Number of subjects: 330
Study 39163592 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-152 (smartphone app-based digital therapeutic)
Number of subjects: 0
Study 39163592 — intervention group
Group type: COMPARATOR
Intervention: Sham DTx (digital working memory exercise with emotionally neutral stimuli)
Number of subjects: 0
Study 39163592 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-152
Number of subjects: 0
Study 39163592 — intervention group
Group type: COMPARATOR
Intervention: Sham DTx
Number of subjects: 0
Study 39163592 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-152 and Sham DTx
Number of subjects: 0
Study 39163699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mean cerebrospinal fluid pressure (CSFP)
Number of subjects: 21
Study 39163699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-driven CSFP peak-to-valley amplitude (CSFPp)
Number of subjects: 21
Study 39163699 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFP during extubation
Number of subjects: 21
Study 39163858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 4 g
Number of subjects: 309
Study 39163858 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 309
Study 39163971 — intervention group
Group type: EXPERIMENTAL
Intervention: Maple syrup
Number of subjects: 42
Study 39163971 — intervention group
Group type: COMPARATOR
Intervention: Sucrose syrup
Number of subjects: 42